Trilaciclib: First Approval

Trilaciclib ( Cosela™) is a small-molecule, short-acting, inhibitor of cyclin-dependent kinases (CDK) 4 and 6 developed by G1 Therapeutics for its myeloprotection and potential antitumor efficacy and safety benefits in combination with cancer chemotherapy. CDKs govern cell cycle progression, and tri...

Full description

Saved in:
Bibliographic Details
Published in:Drugs (New York, N.Y.) N.Y.), 2021-05, Vol.81 (7), p.867-874
Main Author: Dhillon, Sohita
Format: Article
Language:English
Subjects:
AdisInsight Report
Agreements
Anticancer properties
Antitumor activity
Bone marrow
Breast cancer
Cancer therapies
Cell cycle
Cells (biology)
Chemotherapy
Clinical trials
Colorectal cancer
Colorectal carcinoma
Commercialization
Cyclin-dependent kinases
Cytotoxicity
Etoposide
Granulocytes
Hematopoietic stem cells
Internal Medicine
Kinases
Lung cancer
Medicine
Medicine & Public Health
Myelosuppression
Osteoprogenitor cells
Pharmacokinetics
Pharmacology/Toxicology
Pharmacotherapy
Plasma
Platinum
Progenitor cells
Small cell lung carcinoma
Topotecan
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Trilaciclib ( Cosela™) is a small-molecule, short-acting, inhibitor of cyclin-dependent kinases (CDK) 4 and 6 developed by G1 Therapeutics for its myeloprotection and potential antitumor efficacy and safety benefits in combination with cancer chemotherapy. CDKs govern cell cycle progression, and trilaciclib induces a transient, reversible G1 cell cycle arrest of proliferating haematopoietic stem and progenitor cells in bone marrow, thus protecting them from damage during chemotherapy. In February 2021, trilaciclib received its first approval in the USA to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC). Clinical studies in breast cancer, colorectal cancer and small cell lung cancer are underway in several countries. This article summarizes the milestones in the development of trilaciclib leading to this first approval.
ISSN:0012-6667
1179-1950
DOI:10.1007/s40265-021-01508-y